Hubbry Logo
Paracrine signalingParacrine signalingMain
Open search
Paracrine signaling
Community hub
Paracrine signaling
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Paracrine signaling
Paracrine signaling
Paracrine signaling
View on Wikipedia
from Wikipedia

In cellular biology, paracrine signaling is a form of cell signaling, a type of cellular communication in which a cell produces a signal to induce changes in nearby cells, altering the behaviour of those cells. Signaling molecules known as paracrine factors diffuse over a relatively short distance (local action), as opposed to cell signaling by endocrine factors, hormones which travel considerably longer distances via the circulatory system; juxtacrine interactions; and autocrine signaling. Cells that produce paracrine factors secrete them into the immediate extracellular environment. Factors then travel to nearby cells in which the gradient of factor received determines the outcome. However, the exact distance that paracrine factors can travel is not certain.

Overview of signal transduction pathways.

Although paracrine signaling elicits a diverse array of responses in the induced cells, most paracrine factors utilize a relatively streamlined set of receptors and pathways. In fact, different organs in the body - even between different species - are known to utilize a similar sets of paracrine factors in differential development.[1] The highly conserved receptors and pathways can be organized into four major families based on similar structures: fibroblast growth factor (FGF) family, Hedgehog family, Wnt family, and TGF-β superfamily. Binding of a paracrine factor to its respective receptor initiates signal transduction cascades, eliciting different responses.

Paracrine factors induce competent responders

[edit]

In order for paracrine factors to successfully induce a response in the receiving cell, that cell must have the appropriate receptors available on the cell membrane to receive the signals, also known as being competent. Additionally, the responding cell must also have the ability to be mechanistically induced.[citation needed]

Fibroblast growth factor (FGF) family

[edit]

Although the FGF family of paracrine factors has a broad range of functions, major findings support the idea that they primarily stimulate proliferation and differentiation.[2][3] To fulfill many diverse functions, FGFs can be alternatively spliced or even have different initiation codons to create hundreds of different FGF isoforms.[4]

One of the most important functions of the FGF receptors (FGFR) is in limb development. This signaling involves nine different alternatively spliced isoforms of the receptor.[5] Fgf8 and Fgf10 are two of the critical players in limb development. In the forelimb initiation and limb growth in mice, axial (lengthwise) cues from the intermediate mesoderm produces Tbx5, which subsequently signals to the same mesoderm to produce Fgf10. Fgf10 then signals to the ectoderm to begin production of Fgf8, which also stimulates the production of Fgf10. Deletion of Fgf10 results in limbless mice.[6]

Additionally, paracrine signaling of Fgf is essential in the developing eye of chicks. The fgf8 mRNA becomes localized in what differentiates into the neural retina of the optic cup. These cells are in contact with the outer ectoderm cells, which will eventually become the lens.[4]

Phenotype and survival of mice after knockout of some FGFR genes:[5]

FGFR Knockout Gene Survival Phenotype
Fgf1 Viable Unclear
Fgf3 Viable Inner ear, skeletal (tail) differentiation
Fgf4 Lethal Inner cell mass proliferation
Fgf8 Lethal Gastrulation defect, CNS development, limb development
Fgf10 Lethal Development of multiple organs (including limbs, thymus, pituitary)
Fgf17 Viable Cerebellar Development

Receptor tyrosine kinase (RTK) pathway

[edit]

Paracrine signaling through fibroblast growth factors and its respective receptors utilizes the receptor tyrosine pathway. This signaling pathway has been highly studied, using Drosophila eyes and human cancers.[7]

Binding of FGF to FGFR phosphorylates the idle kinase and activates the RTK pathway. This pathway begins at the cell membrane surface, where a ligand binds to its specific receptor. Ligands that bind to RTKs include fibroblast growth factors, epidermal growth factors, platelet-derived growth factors, and stem cell factor.[7] This dimerizes the transmembrane receptor to another RTK receptor, which causes the autophosphorylation and subsequent conformational change of the homodimerized receptor. This conformational change activates the dormant kinase of each RTK on the tyrosine residue. Due to the fact that the receptor spans across the membrane from the extracellular environment, through the lipid bilayer, and into the cytoplasm, the binding of the receptor to the ligand also causes the trans phosphorylation of the cytoplasmic domain of the receptor.[8]

An adaptor protein (such as SOS) recognizes the phosphorylated tyrosine on the receptor. This protein functions as a bridge which connects the RTK to an intermediate protein (such as GNRP), starting the intracellular signaling cascade. In turn, the intermediate protein stimulates GDP-bound Ras to the activated GTP-bound Ras. GAP eventually returns Ras to its inactive state. Activation of Ras has the potential to initiate three signaling pathways downstream of Ras: Ras→Raf→MAP kinase pathway, PI3 kinase pathway, and Ral pathway. Each pathway leads to the activation of transcription factors which enter the nucleus to alter gene expression.[9]

Diagram showing key components of a signal transduction pathway. See the MAPK/ERK pathway article for details.

RTK receptor and cancer

[edit]

Paracrine signaling of growth factors between nearby cells has been shown to exacerbate carcinogenesis. In fact, mutant forms of a single RTK may play a causal role in very different types of cancer. The Kit proto-oncogene encodes a tyrosine kinase receptor whose ligand is a paracrine protein called stem cell factor (SCF), which is important in hematopoiesis (formation of cells in blood).[10] The Kit receptor and related tyrosine kinase receptors actually are inhibitory and effectively suppresses receptor firing. Mutant forms of the Kit receptor, which fire constitutively in a ligand-independent fashion, are found in a diverse array of cancerous malignancies.[11]

RTK pathway and cancer

[edit]

Research on thyroid cancer has elucidated the theory that paracrine signaling may aid in creating tumor microenvironments. Chemokine transcription is upregulated when Ras is in the GTP-bound state. The chemokines are then released from the cell, free to bind to another nearby cell. Paracrine signaling between neighboring cells creates this positive feedback loop. Thus, the constitutive transcription of upregulated proteins form ideal environments for tumors to arise.[citation needed] Effectively, multiple bindings of ligands to the RTK receptors overstimulates the Ras-Raf-MAPK pathway, which overexpresses the mitogenic and invasive capacity of cells.[12]

JAK-STAT pathway

[edit]

In addition to RTK pathway, fibroblast growth factors can also activate the JAK-STAT signaling pathway. Instead of carrying covalently associated tyrosine kinase domains, Jak-STAT receptors form noncovalent complexes with tyrosine kinases of the Jak (Janus kinase) class. These receptors bind are for erythropoietin (important for erythropoiesis), thrombopoietin (important for platelet formation), and interferon (important for mediating immune cell function).[13]

After dimerization of the cytokine receptors following ligand binding, the JAKs transphosphorylate each other. The resulting phosphotyrosines attract STAT proteins. The STAT proteins dimerize and enter the nucleus to act as transcription factors to alter gene expression.[13] In particular, the STATs transcribe genes that aid in cell proliferation and survival – such as myc.[14]

Phenotype and survival of mice after knockout of some JAK or STAT genes:[15]

Knockout Gene Survival Phenotype
Jak1 Lethal Neurologic Deficits
Jak2 Lethal Failure in erythropoiesis
Stat1 Viable Human dwarfism and craniosynostosis syndromes
Stat3 Lethal Tissue specific phenotypes
Stat4 Viable defective IL-12-driven Th1 differentiation, increased susceptibility to intracellular pathogens

Aberrant JAK-STAT pathway and bone mutations

[edit]

The JAK-STAT signaling pathway is instrumental in the development of limbs, specifically in its ability to regulate bone growth through paracrine signaling of cytokines. However, mutations in this pathway have been implicated in severe forms of dwarfism: thanatophoric dysplasia (lethal) and achondroplasic dwarfism (viable).[16] This is due to a mutation in a Fgf gene, causing a premature and constitutive activation of the Stat1 transcription factor. Chondrocyte cell division is prematurely terminated, resulting in lethal dwarfism. Rib and limb bone growth plate cells are not transcribed. Thus, the inability of the rib cage to expand prevents the newborn's breathing.[17]

JAK-STAT pathway and cancer

[edit]

Research on paracrine signaling through the JAK-STAT pathway revealed its potential in activating invasive behavior of ovarian epithelial cells. This epithelial to mesenchymal transition is highly evident in metastasis.[18] Paracrine signaling through the JAK-STAT pathway is necessary in the transition from stationary epithelial cells to mobile mesenchymal cells, which are capable of invading surrounding tissue. Only the JAK-STAT pathway has been found to induce migratory cells.[19]

Hedgehog family

[edit]

The Hedgehog protein family is involved in induction of cell types and the creation of tissue boundaries and patterning and are found in all bilateral organisms. Hedgehog proteins were first discovered and studied in Drosophila. Hedgehog proteins produce key signals for the establishment of limb and body plan of fruit flies as well as homeostasis of adult tissues, involved in late embryogenesis and metamorphosis. At least three "Drosophila" hedgehog homologs have been found in vertebrates: sonic hedgehog, desert hedgehog, and Indian hedgehog. Sonic hedgehog (SHH) has various roles in vertebrae development, mediating signaling and regulating the organization of central nervous system, limb, and somite polarity. Desert hedgehog (DHH) is expressed in the Sertoli cells involved in spermatogenesis. Indian hedgehog (IHH) is expressed in the gut and cartilage, important in postnatal bone growth.[20][21][22]

Hedgehog signaling pathway

[edit]
Production of the CiR transcriptional repressor when Hh is not bound to Patched. In the diagram, "P" represents phosphate.
When Hh is bound to Patched (PTCH), Ci protein is able to act as a transcription factor in the nucleus.

Members of the Hedgehog protein family act by binding to a transmembrane "Patched" receptor, which is bound to the "Smoothened" protein, by which the Hedgehog signal can be transduced. In the absence of Hedgehog, the Patched receptor inhibits Smoothened action. Inhibition of Smoothened causes the Cubitus interruptus (Ci), Fused, and Cos protein complex attached to microtubules to remain intact. In this conformation, the Ci protein is cleaved so that a portion of the protein is allowed to enter the nucleus and act as a transcriptional repressor. In the presence of Hedgehog, Patched no longer inhibits Smoothened. Then active Smoothened protein is able to inhibit PKA and Slimb, so that the Ci protein is not cleaved. This intact Ci protein can enter the nucleus, associate with CPB protein and act as a transcriptional activator, inducing the expression of Hedgehog-response genes.[22][23][24]

Hedgehog signaling pathway and cancer

[edit]

The Hedgehog Signaling pathway is critical in proper tissue patterning and orientation during normal development of most animals. Hedgehog proteins induce cell proliferation in certain cells and differentiations in others. Aberrant activation of the Hedgehog pathway has been implicated in several types of cancers, Basal Cell Carcinoma in particular. This uncontrolled activation of the Hedgehog proteins can be caused by mutations to the signal pathway, which would be ligand independent, or a mutation that causes overexpression of the Hedgehog protein, which would be ligand dependent. In addition, therapy-induced Hedgehog pathway activation has been shown to be necessary for progression of Prostate Cancer tumors after androgen deprivation therapy.[25] This connection between the Hedgehog signaling pathway and human cancers may provide for the possible of therapeutic intervention as treatment for such cancers. The Hedgehog signaling pathway is also involved in normal regulation of stem-cell populations, and required for normal growth and regeneration of damaged organs. This may provide another possible route for tumorigenesis via the Hedgehog pathway.[26][27][28]

Wnt family

[edit]
Figure of the three main pathways of Wnt signaling in biological signal transduction.

The Wnt protein family includes a large number of cysteine-rich glycoproteins. The Wnt proteins activate signal transduction cascades via three different pathways, the canonical Wnt pathway, the noncanonical planar cell polarity (PCP) pathway, and the noncanonical Wnt/Ca2+ pathway. Wnt proteins appear to control a wide range of developmental processes and have been seen as necessary for control of spindle orientation, cell polarity, cadherin mediated adhesion, and early development of embryos in many different organisms. Current research has indicated that deregulation of Wnt signaling plays a role in tumor formation because, at a cellular level, Wnt proteins often regulated cell proliferation, cell morphology, cell motility, and cell fate.[29]

The canonical Wnt signaling pathway

[edit]
Canonical Wnt pathway without Wnt.

In the canonical pathway, Wnt proteins binds to its transmembrane receptor of the Frizzled family of proteins. The binding of Wnt to a Frizzled protein activates the Dishevelled protein. In its active state the Dishevelled protein inhibits the activity of the glycogen synthase kinase 3 (GSK3) enzyme. Normally active GSK3 prevents the dissociation of β-catenin to the APC protein, which results in β-catenin degradation. Thus inhibited GSK3, allows β-catenin to dissociate from APC, accumulate, and travel to nucleus. In the nucleus β-catenin associates with Lef/Tcf transcription factor, which is already working on DNA as a repressor, inhibiting the transcription of the genes it binds. Binding of β-catenin to Lef/Tcf works as a transcription activator, activating the transcription of the Wnt-responsive genes.[30][31][32]

The noncanonical Wnt signaling pathways

[edit]

The noncanonical Wnt pathways provide a signal transduction pathway for Wnt that does not involve β-catenin. In the noncanonical pathways, Wnt affects the actin and microtubular cytoskeleton as well as gene transcription.

The noncanonical planar cell polarity (PCP) pathway

[edit]
Noncanonical Wnt Planar Cell Polarity pathway.

The noncanonical PCP pathway regulates cell morphology, division, and movement. Once again Wnt proteins binds to and activates Frizzled so that Frizzled activates a Dishevelled protein that is tethered to the plasma membrane through a Prickle protein and transmembrane Stbm protein. The active Dishevelled activates RhoA GTPase through Dishevelled associated activator of morphogenesis 1 (Daam1) and the Rac protein. Active RhoA is able to induce cytoskeleton changes by activating Roh-associated kinase (ROCK) and affect gene transcription directly. Active Rac can directly induce cytoskeleton changes and affect gene transcription through activation of JNK.[30][31][32]

The noncanonical Wnt/Ca2+ pathway

[edit]
Noncanonical Wnt/calcium pathway.

The noncanonical Wnt/Ca2+ pathway regulates intracellular calcium levels. Again Wnt binds and activates to Frizzled. In this case however activated Frizzled causes a coupled G-protein to activate a phospholipase (PLC), which interacts with and splits PIP2 into DAG and IP3. IP3 can then bind to a receptor on the endoplasmic reticulum to release intracellular calcium stores, to induce calcium-dependent gene expression.[30][31][32]

Wnt signaling pathways and cancer

[edit]

The Wnt signaling pathways are critical in cell-cell signaling during normal development and embryogenesis and required for maintenance of adult tissue, therefore it is not difficult to understand why disruption in Wnt signaling pathways can promote human degenerative disease and cancer.

The Wnt signaling pathways are complex, involving many different elements, and therefore have many targets for misregulation. Mutations that cause constitutive activation of the Wnt signaling pathway lead to tumor formation and cancer. Aberrant activation of the Wnt pathway can lead to increase cell proliferation. Current research is focused on the action of the Wnt signaling pathway the regulation of stem cell choice to proliferate and self renew. This action of Wnt signaling in the possible control and maintenance of stem cells, may provide a possible treatment in cancers exhibiting aberrant Wnt signaling.[33][34][35]

TGF-β superfamily

[edit]

"TGF" (Transforming Growth Factor) is a family of proteins that includes 33 members that encode dimeric, secreted polypeptides that regulate development.[36] Many developmental processes are under its control including gastrulation, axis symmetry of the body, organ morphogenesis, and tissue homeostasis in adults.[37] All TGF-β ligands bind to either Type I or Type II receptors, to create heterotetramic complexes.[38]

TGF-β pathway

[edit]

The TGF-β pathway regulates many cellular processes in developing embryo and adult organisms, including cell growth, differentiation, apoptosis, and homeostasis. There are five kinds of type II receptors and seven types of type I receptors in humans and other mammals. These receptors are known as "dual-specificity kinases" because their cytoplasmic kinase domain has weak tyrosine kinase activity but strong serine/threonine kinase activity.[39] When a TGF-β superfamily ligand binds to the type II receptor, it recruits a type I receptor and activates it by phosphorylating the serine or threonine residues of its "GS" box.[40] This forms an activation complex that can then phosphorylate SMAD proteins.

SMAD Signaling Pathway Activated by TGF-β

SMAD pathway

[edit]

There are three classes of SMADs:

  1. Receptor-regulated SMAD (R-SMAD)
  2. Common-mediator SMAD (Co-SMAD)
  3. Inhibitory SMAD (I-SMAD)

Examples of SMADs in each class:[41][42][43]

Class SMADs
R-SMAD SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8/9
Co-SMAD SMAD4
I-SMAD SMAD6 and SMAD7

The TGF-β superfamily activates members of the SMAD family, which function as transcription factors. Specifically, the type I receptor, activated by the type II receptor, phosphorylates R-SMADs that then bind to the co-SMAD, SMAD4. The R-SMAD/Co-SMAD forms a complex with importin and enters the nucleus, where they act as transcription factors and either up-regulate or down-regulate in the expression of a target gene.

Specific TGF-β ligands will result in the activation of either the SMAD2/3 or the SMAD1/5 R-SMADs. For instance, when activin, Nodal, or TGF-β ligand binds to the receptors, the phosphorylated receptor complex can activate SMAD2 and SMAD3 through phosphorylation. However, when a BMP ligand binds to the receptors, the phosphorylated receptor complex activates SMAD1 and SMAD5. Then, the Smad2/3 or the Smad1/5 complexes form a dimer complex with SMAD4 and become transcription factors. Though there are many R-SMADs involved in the pathway, there is only one co-SMAD, SMAD4.[44]

Non-SMAD pathway

[edit]

Non-Smad signaling proteins contribute to the responses of the TGF-β pathway in three ways. First, non-Smad signaling pathways phosphorylate the Smads. Second, Smads directly signal to other pathways by communicating directly with other signaling proteins, such as kinases. Finally, the TGF-β receptors directly phosphorylate non-Smad proteins.[45]

Members of TGF-β superfamily

[edit]

1. TGF-β family

[edit]

This family includes TGF-β1, TGF-β2, TGF-β3, and TGF-β5. They are involved in positively and negatively regulation of cell division, the formation of the extracellular matrix between cells, apoptosis, and embryogenesis. They bind to TGF-β type II receptor (TGFBRII).

TGF-β1 stimulates the synthesis of collagen and fibronectin and inhibits the degradation of the extracellular matrix. Ultimately, it increases the production of extracellular matrix by epithelial cells.[38] TGF-β proteins regulate epithelia by controlling where and when they branch to form kidney, lung, and salivary gland ducts.[38]

2. Bone morphogenetic protein (BMPs) family

[edit]

Members of the BMP family were originally found to induce bone formation, as their name suggests. However, BMPs are very multifunctional and can also regulate apoptosis, cell migration, cell division, and differentiation. They also specify the anterior/posterior axis, induce growth, and regulate homeostasis.[36]

The BMPs bind to the bone morphogenetic protein receptor type II (BMPR2). Some of the proteins of the BMP family are BMP4 and BMP7. BMP4 promotes bone formation, causes cell death, or signals the formation of epidermis, depending on the tissue it is acting on. BMP7 is crucial for kidney development, sperm synthesis, and neural tube polarization. Both BMP4 and BMP7 regulate mature ligand stability and processing, including degrading ligands in lysosomes.[36] BMPs act by diffusing from the cells that create them.[46]

Other members of TGF-β superfamily

[edit]

Summary table of TGF-β signaling pathway

[edit]
TGF Beta superfamily ligand Type II Receptor Type I Receptor R-SMADs Co-SMAD Ligand Inhibitors
Activin A ACVR2A ACVR1B (ALK4) SMAD2, SMAD3 SMAD4 Follistatin
GDF1 ACVR2A ACVR1B (ALK4) SMAD2, SMAD3 SMAD4
GDF11 ACVR2B ACVR1B (ALK4), TGFβRI (ALK5) SMAD2, SMAD3 SMAD4
Bone morphogenetic proteins BMPR2 BMPR1A (ALK3), BMPR1B (ALK6) SMAD1 SMAD5, SMAD8 SMAD4 Noggin, Chordin, DAN
Nodal ACVR2B ACVR1B (ALK4), ACVR1C (ALK7) SMAD2, SMAD3 SMAD4 Lefty
TGFβs TGFβRII TGFβRI (ALK5) SMAD2, SMAD3 SMAD4 LTBP1, THBS1, Decorin

Examples

[edit]

Growth factor and clotting factors are paracrine signaling agents. The local action of growth factor signaling plays an especially important role in the development of tissues. Also, retinoic acid, the active form of vitamin A, functions in a paracrine fashion to regulate gene expression during embryonic development in higher animals.[48] In insects, Allatostatin controls growth through paracrine action on the corpora allata.[citation needed]


In mature organisms, paracrine signaling is involved in responses to allergens, tissue repair, the formation of scar tissue, and blood clotting.[citation needed] Histamine is a paracrine that is released by immune cells in the bronchial tree. Histamine causes the smooth muscle cells of the bronchi to constrict, narrowing the airways.[49]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Paracrine signaling

View on Grokipedia
from Grokipedia
Paracrine signaling is a form of intercellular communication in which a cell secretes signaling molecules, often proteins or peptides, that diffuse over short distances through the to bind receptors on nearby target cells, thereby inducing specific responses without entering the bloodstream. The term "paracrine" was coined by pathologist Friedrich Feyrter in 1943 to describe local actions of hormones on neighboring cells, building on earlier 19th-century observations of intercellular influences. This local mode of signaling contrasts with endocrine signaling, where hormones travel via the to distant targets, , where a cell responds to its own secreted factors, and juxtacrine signaling, which involves direct physical contact between adjacent cells. Paracrine factors, such as growth and differentiation factors (GDFs), enable precise coordination of cellular behaviors in tissues. The mechanism of paracrine signaling typically involves the release of ligands into the local microenvironment, where they bind to specific receptors on adjacent cells, triggering intracellular cascades that regulate processes like proliferation, differentiation, and migration. For instance, in the , presynaptic neurons release neurotransmitters such as glutamate or into the synaptic cleft, where they act paracrinely on postsynaptic neurons to propagate electrical signals. In , paracrine signals from families like fibroblast growth factors (FGFs), , Wnt, and transforming growth factor-beta (TGF-β) play critical roles in patterning tissues; for example, Sonic hedgehog (Shh) from the induces ventral formation and differentiation in vertebrate embryos. Paracrine signaling is vital for numerous physiological processes, including embryonic development, where it orchestrates organ induction—such as and limb formation—and maintains tissue in adults. In the , cytokines released by activated immune cells act paracrinely to recruit and modulate nearby leukocytes, amplifying local inflammatory responses. Additionally, it contributes to and , as seen with (VEGF) secreted by hypoxic cells to stimulate nearby endothelial cell . Dysregulation of paracrine pathways is implicated in diseases like cancer, where aberrant signaling promotes tumor growth and .

Introduction and Basics

Definition and Characteristics

Paracrine signaling represents a fundamental mode of intercellular communication wherein a producing cell releases signaling molecules, known as ligands, that diffuse locally to influence nearby target cells within the same tissue microenvironment. These ligands typically act over short distances, ranging from tens to several hundred micrometers (up to approximately 300 μm), enabling precise, localized coordination without entering the systemic circulation. Key characteristics of paracrine signaling include the reliance on for ligand transport, which results in rapid onset and often transient effects on responsive target cells equipped with appropriate receptors. The process involves soluble factors such as growth factors and cytokines, which are secreted into the and bind to surface or intracellular receptors on adjacent cells, triggering downstream cascades. This mechanism requires the presence of competent responder cells, as not all nearby cells may express the necessary receptors, ensuring specificity in cellular responses. The spatial extent of paracrine signaling is constrained by several factors, including the that impedes , the establishment of concentration gradients as ligands spread from the source, and enzymatic degradation that limits ligand half-life and range. Effective signaling distances are generally confined to approximately 25 cell diameters or less, preventing unintended broad dissemination. Ligands encompass diverse chemical classes, including peptides and proteins (e.g., fibroblast growth factors), lipids, and even gases such as , which exemplifies a highly diffusible paracrine signal in contexts like . Biologically, paracrine signaling plays a crucial role in orchestrating tissue patterning during development, modulating inflammatory responses through release, and facilitating by promoting and proliferation at injury sites, all while avoiding widespread systemic impacts. For instance, it coordinates by inducing localized changes in neighboring cells, and in wound repair, it activates processes like ATP-mediated danger signaling to initiate regeneration. Unlike endocrine signaling, which propagates hormones via the bloodstream to distant organs, paracrine effects remain confined to immediate vicinities.

Historical Development

The concept of paracrine signaling emerged from early 20th-century observations in , particularly through experiments demonstrating local inductive effects in embryos. In the , and Hilde Mangold's transplantation studies in embryos revealed the "organizer" region, where tissue extracts induced neural tissue formation in nearby cells via diffusible substances, representing an early example of short-range signaling distinct from systemic hormonal effects. This work, awarded the in Physiology or Medicine to Spemann, laid foundational insights into localized cellular communication during embryogenesis. The term "paracrine" was coined in the mid-20th century by Austrian pathologist Friedrich Feyrter, who in 1938 described dispersed "clear cells" (Helle Zellen) in epithelial tissues capable of local secretory actions, and formalized the concept in his 1953 book Über die peripheren endokrinen (parakrinen) Drüsen des Menschen to distinguish short-distance cellular interactions from endocrine signaling via the bloodstream. Building on this, the 1950s saw the identification of specific paracrine factors, notably (NGF) by and Viktor Hamburger, who used chick embryo and mouse tumor extracts to demonstrate NGF's role in promoting local nerve cell growth and differentiation. Their collaborative efforts, culminating in the 1986 in or shared with Stanley , established NGF as the first recognized paracrine mediator. Paracrine signaling was further formalized in the through studies that isolated and characterized growth-promoting factors in controlled environments, enabling precise measurement of local effects without systemic interference. By the , the identification of fibroblast growth factors (FGFs), such as FGF-1 and FGF-2, highlighted their paracrine roles in tissue repair, , and development, with experiments showing FGFs secreted by fibroblasts influencing nearby endothelial and epithelial cells. The 1990s advanced understanding via genetic models in and mice, where paracrine pathways like and Wnt were dissected for their roles in embryonic patterning and , revealing conserved mechanisms across . In the molecular era post-2000, genomic approaches integrated paracrine signaling into complex networks, particularly in niches, where high-throughput sequencing uncovered interactions like Wnt and Notch pathways maintaining quiescence and differentiation through local cues in hematopoietic and neural environments.

Comparison to Other Signaling Types

Autocrine and Endocrine Signaling

refers to the process by which a cell produces and secretes signaling molecules, or ligands, that bind to receptors on its own surface, thereby influencing its own behavior and function. This self-stimulatory mechanism allows cells to amplify or regulate their responses to internal or external cues, often promoting processes such as proliferation or survival in clusters of identical cells. A classic example is observed in immune cells, where T lymphocytes secrete growth factors like that bind back to their own receptors, driving clonal expansion during an . In pathological contexts, such as tumor growth, cancer cells exploit autocrine loops to sustain uncontrolled proliferation by producing their own growth factors. In contrast, endocrine signaling involves the secretion of hormones by specialized endocrine cells, which are then transported through the bloodstream to act on distant target cells throughout the body. This long-range communication enables systemic of physiological processes, such as , growth, and , but typically results in slower onset due to the time required for circulation and dilution in the blood. Hormones operate at low concentrations, often below 10^{-8} M, and bind to specific receptors on target cells to initiate . For instance, insulin, produced by beta cells in the , travels via the bloodstream to regulate in distant tissues like liver and muscle cells. The key differences between autocrine, endocrine, and paracrine signaling lie primarily in the range and mode of delivery: autocrine acts on the same cell (intracellular scope), endocrine employs systemic transport for long-range effects, and paracrine involves short-range to nearby cells without bloodstream involvement. While all three types utilize similar ligands and receptor-mediated transduction pathways, autocrine and endocrine signals differ from paracrine in their potential for broader or self-contained impact, with endocrine being slower and more dilute compared to the rapid, localized action of paracrine . Overlaps occur in hybrid scenarios, fine-tuning secretion through local and systemic feedbacks. From an evolutionary perspective, endocrine signaling represents an ancient systemic control mechanism that likely arose early in metazoan history, evolving from primitive chemical communication systems like pheromones to coordinate organism-wide responses in complex multicellular organisms. In parallel, autocrine and paracrine signaling provided fine-tuned local regulation, enabling adaptive responses at the cellular and tissue levels, with evidence suggesting their co-evolution alongside endocrine pathways for integrated physiological control.

Juxtacrine Signaling

Juxtacrine signaling represents a contact-dependent mode of intercellular communication in which signaling occurs directly between adjacent cells through interactions between membrane-anchored ligands on one cell and receptors on the neighboring cell, without the release of diffusible factors. This contrasts with paracrine signaling's reliance on secreted ligands that diffuse short distances to target cells. The term "juxtacrine" was introduced in 1990 to describe such membrane-bound interactions, exemplified by the binding of pro-transforming growth factor alpha (TGF-α) to (EGFR) on adjacent cells, promoting and localized . The mechanism of juxtacrine signaling necessitates physical cell-cell adhesion, often mediated by adhesion molecules such as cadherins, which stabilize contacts and facilitate the presentation of signaling ligands, or gap junctions, which permit the direct passage of small ions and metabolites between cytoplasms. Upon adhesion, the ligand-receptor complex triggers intracellular signal transduction cascades, typically involving proteolytic processing or conformational changes that activate downstream effectors without intermediary diffusion steps. This direct coupling ensures rapid signal initiation, often within seconds of contact, and high spatial precision confined to the site of interaction. A prominent example is the Notch-Delta pathway, where the membrane-bound Delta ligand on a signaling cell binds the Notch receptor on an adjacent cell, inducing successive proteolytic cleavages that release the Notch intracellular domain (NICD) to translocate to the nucleus and regulate for during development. In , this interaction determines cell fates by promoting differentiation in one cell while maintaining progenitor status in the neighbor, as demonstrated in and models. Another key instance occurs in the , where the forms between a and an , enabling juxtacrine interactions via clustered T cell receptors (TCRs) with peptide-MHC complexes, alongside costimulatory molecules like binding B7 ligands. This synapse coordinates T cell activation, integrating adhesion and signaling to amplify immune responses while preventing inappropriate activation. Unlike paracrine signals, these contact-based exchanges allow for immediate, unidirectional control of effector functions, such as polarization, but restrict influence to physically apposed cells. In biological contexts, juxtacrine signaling plays critical roles in during embryonic development, where it enforces binary decisions like or somitogenesis through pathways like Notch, ensuring patterned tissue organization. It also coordinates immune responses by facilitating precise T cell-antigen presenting cell dialogues at the , which sustain activation signals and direct adaptive immunity without broader . These roles highlight juxtacrine signaling's advantage in speed and specificity for short-range, high-fidelity interactions essential for multicellular coordination.

General Mechanisms

Ligand Production and Secretion

Paracrine signaling ligands are primarily proteins and peptides, though some are or gases, synthesized and released to act on nearby cells. Proteins and peptides, such as growth factors and cytokines, constitute the majority and are produced through the classical secretory pathway, involving synthesis as polypeptides from via ribosomal . , including eicosanoids like prostaglandins, are derived from membrane phospholipids such as through enzymatic pathways. Gases, exemplified by (NO), are generated on-demand from precursors like L-arginine by enzymes such as (NOS). These diverse ligand types ensure rapid, localized communication while their production limits to short ranges. The biosynthesis of protein and peptide ligands begins with in the nucleus, where environmental or intracellular signals activate specific promoters to express ligand-encoding genes. occurs on ribosomes, producing nascent polypeptides that contain an N-terminal directing them to the (ER) for co-translational translocation. In the ER, initial folding and quality control occur, followed by transport to the Golgi apparatus via COPII-coated vesicles. Post-translational modifications (PTMs) are critical, including N-linked in the ER for stability and O-linked in the Golgi for further maturation; proteolytic cleavage often converts pro-ligands to active forms, such as the processing of precursor s. and gas ligands bypass this pathway, with lipids formed via or enzymes and gases synthesized enzymatically without vesicular transport. Secretion of protein and peptide ligands occurs primarily through , where mature ligands are packaged into secretory vesicles budding from the trans-Golgi network. Two main modes exist: constitutive secretion, which releases ligands continuously via default vesicles fusing with the plasma membrane, and regulated secretion, triggered by stimuli like calcium influx to mobilize storage granules. Vesicle fusion is mediated by SNARE proteins, which form complexes to dock vesicles to the target membrane, ensuring precise delivery. Lipid ligands diffuse directly from the membrane after synthesis, while gases like NO cross membranes freely due to their small size and , without requiring vesicular mechanisms. Regulation of ligand production and secretion integrates transcriptional, post-transcriptional, and environmental controls to fine-tune paracrine responses. Feedback loops, such as negative autoregulation where secreted ligands suppress their own , maintain . Environmental cues prominently influence secretion; for instance, hypoxia stabilizes hypoxia-inducible factor-1α (HIF-1α), which transcriptionally upregulates (VEGF) production and release to promote in adjacent tissues. Inflammatory signals like tumor necrosis factor-α (TNF-α) can enhance ligand synthesis via activation. To restrict paracrine signaling to local effects, ligands undergo rapid clearance primarily through enzymatic degradation in the . Matrix metalloproteinases (MMPs), such as MMP-2 and MMP-9, proteolytically cleave protein ligands and their extracellular matrix-binding partners, limiting and . For gases like NO, spontaneous chemical reactions and enzymatic breakdown by contribute to their short of seconds to minutes.

Receptor Binding and Signal Transduction

In paracrine signaling, ligands secreted by a signaling cell diffuse through the via concentration gradients, enabling them to reach and to specific receptors on nearby target cells. This binding is highly specific, governed by the structural complementarity between the and receptor, which ensures selective activation of target cells while minimizing off-target effects. The affinity of the -receptor interaction, often in the nanomolar range, further dictates the efficiency of binding, with higher affinity promoting stable complexes even at low concentrations typical of local gradients. Upon binding, receptors undergo conformational changes that initiate , with common receptor types including G protein-coupled receptors (GPCRs), receptor kinases (RTKs), and cytokine receptors. GPCRs, which span the plasma membrane seven times, activate heterotrimeric G proteins upon ligand engagement, leading to the dissociation of Gα and Gβγ subunits that modulate downstream effectors. RTKs and cytokine receptors frequently dimerize or oligomerize in response to ligand binding, a process that stabilizes the receptor complex and exposes intracellular kinase domains for activation. For instance, in RTKs, dimerization induces autophosphorylation on residues, creating docking sites for adaptor proteins, while cytokine receptors recruit Janus kinases (JAKs) to initiate events. Signal transduction propagates the extracellular signal intracellularly through cascades involving second messengers, kinase activations, and transcription factor modulation. GPCRs commonly generate second messengers such as cyclic AMP () via adenylyl cyclase activation or inositol trisphosphate (IP3) and diacylglycerol (DAG) through phospholipase C, which respectively elevate intracellular calcium or activate protein kinase C. In RTKs and cytokine receptors, transduction relies on sequential kinase phosphorylations that relay the signal from the membrane to the cytosol and nucleus, ultimately activating transcription factors like those in the STAT family or MAPK pathway components. These mechanisms convert the initial binding event into diverse cellular responses, such as gene expression changes or metabolic adjustments. Signal amplification occurs as each transduction step activates multiple downstream molecules, exponentially increasing the response magnitude from a single ligand-receptor interaction. For example, one activated can stimulate numerous molecules to produce thousands of cAMP molecules, while cascades propagate phosphorylations to amplify the signal up to 10^4-fold in some systems. This relay ensures robust cellular responses despite transient, low-concentration paracrine signals. To prevent prolonged activation and maintain cellular homeostasis, signals are terminated through multiple mechanisms, including receptor desensitization, dephosphorylation by phosphatases, and endocytosis. Desensitization often involves phosphorylation of the receptor by kinases like G protein-coupled receptor kinases (GRKs), which recruits arrestins to block further G protein coupling in GPCRs. Phosphatases, such as protein tyrosine phosphatases (PTPs), rapidly reverse phosphorylation events in kinase-based pathways, restoring receptors and effectors to their inactive states. Endocytosis internalizes ligand-bound receptors via clathrin-coated pits, reducing surface availability and directing receptors for degradation or recycling, thereby attenuating signaling within minutes to hours.

Key Paracrine Signaling Families

Fibroblast Growth Factor (FGF) Family

The fibroblast growth factor (FGF) family consists of 22 structurally related members in humans (FGF1–FGF23), which function predominantly as paracrine signals to coordinate cellular behaviors such as proliferation, differentiation, , and migration during development and tissue . These ligands are synthesized as precursor proteins and secreted, with the paracrine subtypes (FGF1–10, FGF16–18, FGF20, and FGF22) acting locally on nearby cells via high-affinity receptor interactions, in contrast to the endocrine subtypes (FGF19, FGF21, and FGF23) that exert systemic effects through circulation. The remaining members (FGF11–14) operate intracellularly as factors without . Structurally, all FGFs share a conserved β-trefoil core fold composed of 12 antiparallel β-strands arranged into three β-sheets (β1–β3), which provides stability and serves as the primary interface for receptor binding. This fold is flanked by N- and C-terminal extensions that vary among family members, influencing specificity and activity. A key feature is the presence of heparin-binding domains, typically involving basic residues like and on the protein surface, which enable interactions with the and essential co-receptors to facilitate localized signaling gradients. In angiogenesis, FGF2 exemplifies paracrine action by stimulating endothelial cell migration and proliferation to form new vessels, often synergizing with (VEGF) to amplify vascular remodeling in ischemic tissues and . For osteogenesis, FGFs such as FGF2 and FGF9 promote mesenchymal stem cell commitment to osteoblasts, enhance matrix mineralization, and support endochondral bone formation, as evidenced by their roles in regulating proliferation and during skeletal growth. Paracrine FGFs exert their effects through binding to one of four receptor kinases, FGFR1–FGFR4, which feature three extracellular immunoglobulin-like domains for recognition, a single transmembrane , and an intracellular split domain that initiates signaling upon activation. generates isoforms (e.g., IIIb and IIIc in FGFR1–3) that confer specificity, while co-receptors like proteoglycans (HSPGs) are required for complex assembly, stabilizing the ternary FGF-FGFR-HSPG interaction and preventing beyond local sites. Expression of FGF family members is dynamically regulated, with broad, often ubiquitous patterns in embryonic tissues to drive morphogenetic processes like limb bud outgrowth and . In adults, expression is more tissue-specific and context-dependent; for instance, FGF7 ( growth factor) is restricted to mesenchymal cells in the , where it signals paracrinely to adjacent epithelial cells to stimulate proliferation and barrier repair following injury.

Hedgehog Family

The Hedgehog (Hh) family of signaling proteins constitutes a key paracrine signaling system conserved across metazoans, with a single homolog, (Hh), in and three paralogs in mammals: Sonic hedgehog (Shh), Indian hedgehog (Ihh), and (Dhh). These proteins are morphogens that pattern tissues during development and maintain in adults, acting over short to long ranges depending on context. Structurally, mature Hh ligands derive from autocatalytic cleavage of precursor proteins, yielding an N-terminal signaling domain (~19 kDa) tethered to the cell membrane via dual lipid modifications: cholesterol conjugation at the C-terminus and N-terminal palmitoylation mediated by the acyltransferase Skinny hedgehog (Skn in Drosophila) or Hedgehog acyltransferase (HHAT in mammals). These hydrophobic anchors restrict Hh to the producing cell surface, enabling localized paracrine effects, while the N-terminal domain retains the core signaling activity essential for receptor interaction. Hh signaling plays critical roles in anterior-posterior patterning of the limb buds and ventral regions during embryogenesis, where Shh gradients specify digit identities and neural fates, respectively. In adults, Ihh and contribute to gut by regulating epithelial-mesenchymal interactions that support intestinal maintenance and barrier integrity. The primary receptors for Hh ligands are the family proteins, which in the absence of ligand actively inhibit the G-protein-coupled receptor (SMO) through mechanisms involving transport. Upon Hh binding to PTCH, this inhibition is relieved, allowing SMO activation and downstream . In mammals, serves as the dominant receptor for all three Hh paralogs. To control signaling range, Hh ligands undergo multimerization into soluble complexes facilitated by palmitoylation, which promotes long-range diffusion, while release from the membrane requires the multipass Dispatched (Disp). Dispatched interacts with the cholesterol-modified to enable Hh shedding, restricting paracrine spread to appropriate distances in tissues.

Wnt Family

The Wnt family comprises 19 secreted glycoproteins in humans, each approximately 350–400 in length and characterized by conserved residues that facilitate bond formation for structural stability.01075-9) These proteins undergo critical post-translational modifications, including N-glycosylation and palmitoleoylation at a conserved serine residue, which enhances their hydrophobicity and influences their signaling range. The lipid modification, specifically the attachment of , is essential for Wnt activity but poses significant challenges to , often resulting in limited diffusion and predominantly local paracrine effects due to association with cell membranes or extracellular vesicles. Wnt secretion begins in the (ER), where the O-acyltransferase (PORCN) catalyzes the palmitoleoylation of Wnt proteins, a process indispensable for their proper folding and biological function. Following lipidation, Wnt proteins bind to the dedicated cargo receptor Wntless (WLS), a multipass that shuttles them through the Golgi apparatus to the plasma membrane for via multivesicular bodies. Disruptions in this pathway, such as PORCN mutations, severely impair Wnt release, underscoring the intricate coordination required to overcome the proteins' poor solubility and ensure effective paracrine delivery to nearby cells. In terms of functions, Wnt signaling promotes renewal, notably in the intestinal crypts where it maintains proliferative compartments essential for epithelial . Additionally, Wnts guide in the by modulating dynamics and directing neuronal polarity through localized gradients. These roles highlight Wnt's versatility in regulating , migration, and tissue organization via paracrine cues. Wnt ligands primarily engage the seven-transmembrane (FZD) receptor family, consisting of 10 members in humans, which recognize specific Wnt subtypes with varying affinities. signaling typically requires co-receptors LRP5 or LRP6, receptor-related proteins that stabilize the receptor complex upon Wnt binding, whereas noncanonical pathways often proceed independently of these co-receptors. The duality of (β-catenin-dependent) and noncanonical branches allows Wnts to diversely influence and polarity, with pathway variants detailed in the Canonical and Noncanonical Wnt Pathways section.

TGF-β Superfamily

The β (TGF-β) superfamily encompasses over 30 structurally related secreted proteins that play critical roles in paracrine signaling, regulating cellular processes such as proliferation, differentiation, and across diverse tissues. Key members include the three TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3), bone morphogenetic proteins (BMPs), activins, and growth and differentiation factors (GDFs), which collectively influence embryonic development, tissue , and repair. These ligands are synthesized as precursor proteins that undergo proteolytic processing to yield mature, bioactive dimers essential for their signaling functions. Structurally, TGF-β superfamily members feature a conserved cysteine knot motif, where nine residues form intramolecular bonds that stabilize an extended β-sheet fold, enabling the formation of disulfide-linked homodimers or heterodimers. Many, particularly the TGF-βs, are secreted in a latent form bound to a latency-associated (LAP), which must be cleaved or proteolytically activated—often by or matrix metalloproteinases—to release the mature for receptor binding. This latency mechanism ensures spatial and temporal control of signaling in paracrine contexts. The superfamily exhibits multifunctional roles, including the induction of epithelial-mesenchymal transition (EMT) by TGF-β isoforms, which promotes cell motility and is vital for developmental and . TGF-βs also mediate immune suppression by inhibiting T-cell proliferation and promoting regulatory T-cell differentiation, thereby maintaining immune . In contrast, BMPs drive bone formation by stimulating osteoblast differentiation and mineralization, as exemplified by and BMP-7 in fracture repair and skeletal development. Signaling is initiated through binding to heterotetrameric complexes of type I and type II serine/ receptors, where the ligand-bound type II receptor phosphorylates and activates the type I receptor, propagating intracellular signals. The superfamily is phylogenetically divided into two major branches: the TGF-β/activin branch, comprising TGF-βs, activins, nodal, and inhibins with roles in inhibition and differentiation; and the BMP/GDF branch, including BMPs and GDFs that predominantly promote proliferation and patterning. These branches utilize distinct receptor combinations and effector pathways, such as SMAD-dependent transcription, to elicit branch-specific responses.

Pathways in Specific Families

Receptor Tyrosine Kinase (RTK) Pathways

Receptor tyrosine kinases (RTKs) are a major class of cell surface receptors involved in paracrine signaling, characterized by a modular structure that enables ligand binding and intracellular signal transduction. These receptors typically consist of an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular region containing a tyrosine kinase domain responsible for phosphorylating tyrosine residues. The extracellular domain varies among RTK families to confer ligand specificity, while the conserved intracellular kinase domain allows for autophosphorylation upon activation, creating docking sites for downstream signaling molecules. In paracrine signaling, RTKs are activated by soluble ligands that diffuse locally to nearby cells, with the fibroblast growth factor (FGF) family serving as a prominent example. FGF ligands bind to the extracellular domain of FGFRs (a subset of RTKs), inducing receptor dimerization and stabilizing the active conformation. This dimerization brings the intracellular kinase domains into proximity, leading to trans-autophosphorylation on specific tyrosine residues within the activation loop and juxtamembrane region. Autophosphorylation not only enhances kinase activity but also generates phosphotyrosine motifs that recruit adaptor and effector proteins, initiating diverse intracellular cascades. Downstream signaling from activated RTKs, particularly FGFRs, branches into several key pathways that regulate cellular processes such as proliferation, , and migration. The RAS-MAPK pathway is prominently activated through of the adaptor protein and , leading to RAS activation, sequential of RAF, MEK, and ERK kinases, and ultimately transcription factor modulation that promotes . Parallelly, the PI3K-AKT pathway is engaged via of GAB1 and PI3K, resulting in PIP3 production, AKT , and inhibition of to enhance . Additionally, the PLCγ pathway is triggered by direct of PLCγ, hydrolyzing PIP2 to generate IP3 and DAG, which mobilize intracellular calcium and activate PKC for short-term responses like cytoskeletal reorganization. Signal specificity in RTK pathways, exemplified by FGF signaling, is achieved through docking proteins that selectively couple receptors to downstream effectors. In FGFRs, the adaptor FRS2α binds constitutively to the juxtamembrane region and becomes phosphorylated upon activation, serving as a primary scaffold for GRB2-SOS recruitment to the RAS-MAPK pathway and GAB1-PI3K linkage for AKT signaling. This FRS2-mediated organization ensures efficient and targeted signal propagation. RTK pathways also exhibit cross-talk with other signaling routes, such as integration with STAT transcription factors, allowing contextual modulation of responses in paracrine environments.

JAK-STAT Pathways

The JAK-STAT pathway represents a direct -to-nucleus signaling mechanism essential for paracrine communication, characterized by its rapidity in gene regulation. It comprises Janus kinases (JAKs)—non-receptor kinases including JAK1, JAK2, JAK3, and TYK2—that constitutively associate with the cytoplasmic domains of receptors—and signal transducers and activators of transcription (STATs), a family of latent transcription factors (–STAT6). Upon binding of paracrine ligands such as to their receptors, the receptors dimerize or oligomerize, juxtaposing associated JAKs for mutual transphosphorylation and activation. The activated JAKs then phosphorylate specific residues on the receptor tails, generating docking sites that recruit and phosphorylate cytoplasmic STATs; phosphorylated STATs subsequently homodimerize or heterodimerize, translocate to the nucleus, and bind to gamma-activated sites (GAS) in promoter regions to drive transcription of target genes. In paracrine contexts, the JAK-STAT pathway is prominently activated by locally secreted s, such as interleukin-6 (IL-6), which signals through the IL-6 receptor complex to induce inflammatory responses and production in nearby cells. Links to other paracrine factors exist via cross-activation; for instance, (FGF) signaling through receptor tyrosine kinases can indirectly engage JAK-STAT by recruiting non-receptor tyrosine kinases, thereby integrating growth cues with cytokine responses. This pathway's role in rapid, local signaling is exemplified in developmental processes, such as the JAK-STAT-dependent migration of border cells in the Drosophila ovary, where Unpaired ligands act paracrine to trigger invasive behavior. Downstream of activation, STAT dimers regulate genes involved in proliferation, differentiation, and immune modulation, including the suppressors of signaling (SOCS) family, which exert by binding JAKs to inhibit further and pathway activity. Pathway variations confer specificity: and STAT2 are chiefly activated by type I interferons to promote antiviral states, whereas and STAT5 respond to growth-promoting cytokines and factors, supporting cell survival and proliferation. Unlike cascades that rely on second messengers, JAK-STAT signaling proceeds directly without intermediates, though it can intersect with RTK pathways like FGF for enhanced paracrine coordination.

Canonical and Noncanonical Wnt Pathways

The , a key paracrine mechanism, bifurcates into canonical and noncanonical branches that enable diverse cellular responses such as proliferation, polarity, and migration through secreted Wnt ligands acting over short distances. In the canonical pathway, Wnt ligands bind to (FZD) receptors and the co-receptor /6, recruiting (DVL) to inhibit the β-catenin destruction complex composed of Axin, , GSK3β, and CK1. This inhibition stabilizes β-catenin, allowing its accumulation in the cytoplasm and subsequent nuclear translocation, where it forms a complex with TCF/LEF transcription factors to activate target involved in . Noncanonical Wnt signaling encompasses β-catenin-independent pathways, primarily the planar cell polarity (PCP) and Wnt/Ca²⁺ branches, which regulate cytoskeletal dynamics and calcium-mediated responses without relying on transcriptional changes. In the PCP pathway, Wnt ligands interact with FZD and co-receptor ROR1/2, activating DVL to engage downstream effectors like Rho and JNK, which orchestrate cytoskeletal reorganization for processes such as convergent extension during . For example, in embryos, PCP signaling directs polarized cell movements essential for tissue . The Wnt/Ca²⁺ pathway, another noncanonical arm, involves Wnt binding to FZD receptors coupled with G-proteins, leading to activation of (PLC), production of IP₃, and release of intracellular Ca²⁺ stores, which in turn activates (PKC) and to dephosphorylate NFAT for its nuclear translocation and gene regulation. This pathway modulates and motility in a rapid, non-transcriptional manner. The choice between and noncanonical Wnt signaling is context-dependent, influenced by co-receptor availability such as , which promotes PCP activation while suppressing β-catenin stabilization, allowing cells to toggle pathways based on ligand-receptor combinations and cellular environment. In paracrine contexts, Wnt ligands form concentration gradients via mechanisms like filopodia-mediated transport or binding, enabling spatial patterning of target tissues during development. For instance, graded Wnt distribution instructs anterior-posterior axis formation in embryos by differentially activating pathway branches in receiving cells.

SMAD and Non-SMAD Pathways in TGF-β

The transforming growth factor-β (TGF-β) superfamily signals primarily through the canonical SMAD pathway, where ligand binding to type II and type I receptors (TβRII and TβRI) leads to TβRII-mediated of TβRI, which in turn receptor-regulated SMADs (R-SMADs). For TGF-β, the primary R-SMADs activated are SMAD2 and SMAD3, while bone morphogenetic proteins (BMPs) preferentially activate SMAD1, SMAD5, and SMAD8. Phosphorylated R-SMADs then form heteromeric complexes with the common mediator SMAD4, enabling nuclear translocation where these complexes bind to specific DNA sequences, such as SMAD-binding elements (SBEs) like GTCT motifs, often in cooperation with co-activators such as FOXH1 to regulate target gene transcription. A classic example is the induction of (PAI-1), which promotes deposition and is transcriptionally upregulated via SMAD complexes. Regulation of the SMAD pathway occurs at multiple levels to fine-tune cellular responses. Inhibitory SMADs, SMAD6 and SMAD7, antagonize signaling by competing with R-SMADs for receptor binding, preventing their , or by recruiting E3 ubiquitin ligases like SMURF1/2 to promote receptor or SMAD degradation. SMAD7, in particular, forms a complex with SMURF2 to ate TβRI, leading to its proteasomal degradation and signal termination. Additionally, post-translational modifications, such as linker region of R-SMADs by kinases like MAPK or CDK8/9, can modulate their activity, nuclear retention, or degradation, thereby integrating inputs from other pathways. In parallel to the SMAD pathway, TGF-β activates non-SMAD branches that contribute to diverse outcomes like , , and cytoskeletal reorganization. TβRI can directly activate (MAPK) pathways, including ERK1/2, via adaptor proteins such as SHC//, leading to regulation of and migration. Another key non-SMAD route involves TGF-β-associated kinase 1 (TAK1), recruited via TRAF6 ubiquitination of the receptor complex, which phosphorylates and activates p38 MAPK, JNK, or , promoting stress responses, , or inflammatory cytokine production. These pathways often synergize or antagonize SMAD signaling; for instance, TAK1-mediated p38 activation can enhance SMAD-induced transcription in some contexts while driving epithelial-to-mesenchymal transition (EMT) independently in others. Branch specificity within the TGF-β superfamily underscores functional diversity: TGF-β/SMAD2/3 signaling typically induces growth arrest and fibrosis through targets like p15^INK4B and PAI-1, whereas BMP/SMAD1/5/8 promotes differentiation and osteogenesis via genes such as ID1 and Runx2. This selectivity arises from receptor-specific domains that dictate R-SMAD and downstream partnerships. Cross-regulation with other pathways, such as Wnt, further modulates TGF-β responses; for example, SMAD3/4 complexes can interact with β-catenin to co-activate transcription of genes involved in EMT or inhibit differentiation. Such interactions highlight how SMAD and non-SMAD arms integrate extracellular cues to determine cell fate.

Physiological Roles

Embryonic Development and Morphogenesis

Paracrine signaling plays a pivotal role in embryonic development by establishing gradients that pattern tissues and direct cell fate decisions. These gradients, formed by secreted molecules diffusing from localized sources, create concentration-dependent signals that instruct cells to adopt specific identities over short ranges, typically micrometers to millimeters. For instance, in the vertebrate , Sonic Hedgehog (Shh), a member of the Hedgehog family, emanates from the and floor plate to form a ventral-to-dorsal gradient, specifying distinct neuronal subtypes such as floor plate cells at high concentrations and motor neurons at intermediate levels. This process ensures precise dorsoventral patterning, with disruptions in Shh gradient formation leading to severe neural defects in knockouts. Members of key paracrine signaling families contribute uniquely to embryonic patterning. The (FGF) family drives limb bud outgrowth through paracrine loops between the apical ectodermal ridge (AER) and underlying ; for example, FGF8 and maintain proliferation and proximodistal axis elongation in chick and embryos. Wnt signaling establishes anterior-posterior axis polarity, with canonical Wnt ligands from the posterior promoting formation during in and models. In dorsoventral polarity, bone morphogenetic proteins (BMPs) from the TGF-β superfamily form gradients opposed by dorsal antagonists like Chordin, patterning the in embryos where BMP inhibition specifies neural tissue. Hedgehog signaling, particularly Shh, also regulates somitogenesis by timing presomitic segmentation in and chick, ensuring rhythmic formation of somites along the axis. Beyond patterning, paracrine cues orchestrate during and . In , FGF and Wnt gradients induce mesendoderm formation and cell movements in , coordinating and convergence-extension. For , TGF-β signaling directs endocardial-to-mesenchymal transition in cardiac cushions, essential for formation in embryos, where paracrine BMP and TGF-β ligands promote remodeling. These interactions highlight how paracrine signals integrate to shape tissue architecture. Cell competence, the ability of responding cells to interpret paracrine signals, is modulated by prior exposures that prime receptors and transcription factors. In neural induction, competence in ectodermal cells is established by early Wnt and FGF priming, enabling subsequent BMP inhibition to trigger neural fate in . Insights from model organisms underscore these mechanisms: embryos reveal rapid paracrine dynamics in axis formation via microinjections, chick limb buds demonstrate AER-mesenchyme feedback through bead implants, and mouse knockouts quantify patterning defects, such as Shh-null closure failures. These models collectively affirm paracrine signaling's precision in .

Adult Tissue Maintenance and Repair

In adult tissues, paracrine signaling plays a crucial role in maintaining by regulating niches. In the , Wnt ligands secreted by Paneth cells and mesenchymal stromal cells act in a paracrine manner to activate canonical Wnt/β-catenin signaling in intestinal s (ISCs), promoting their self-renewal and differentiation to sustain epithelial turnover. Similarly, in hair follicles, Sonic Hedgehog (Shh) signaling from follicular epithelial cells provides paracrine cues to dermal papilla cells and bulge s, ensuring cyclic regeneration and preventing premature entry into the resting phase during the hair cycle. These niche signals create localized microenvironments that balance proliferation and quiescence, preventing aberrant growth while supporting steady-state tissue renewal. Paracrine mechanisms are equally vital for tissue repair following injury, orchestrating inflammation and vascularization. During the initial inflammatory phase of wound healing, damaged cells release cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) in a paracrine fashion, recruiting circulating monocytes that differentiate into macrophages to clear debris and modulate the immune response. In parallel, fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF) secreted by endothelial cells, fibroblasts, and macrophages promote angiogenesis by stimulating endothelial proliferation and tube formation, ensuring nutrient delivery to the healing site. Tissue-specific examples highlight this precision: in liver regeneration after partial hepatectomy, hepatocyte growth factor (HGF) produced by sinusoidal endothelial cells and hepatic stellate cells acts paracrine on c-Met receptors in hepatocytes, driving their proliferation to restore liver mass. In bone remodeling, bone morphogenetic proteins (BMPs), particularly BMP-2 and BMP-7, are released by osteoblasts and osteocytes to paracrine influence osteoclast differentiation and activity via Smad signaling, coupling bone resorption with formation to maintain skeletal integrity. Negative feedback loops mediated by paracrine signals prevent excessive repair and overgrowth, preserving . Transforming growth factor-β (TGF-β) isoforms, secreted by various stromal and immune cells, inhibit epithelial and proliferation through Smad-dependent pathways, counteracting pro-regenerative signals like Wnt or HGF to terminate regenerative responses and avoid . With aging, paracrine signaling efficiency declines, contributing to exhaustion and impaired tissue maintenance. In aged niches, reduced secretion of supportive factors such as Wnt or HGF from stromal cells leads to diminished responsiveness, resulting in slower regeneration and accumulation of senescent cells that further disrupt paracrine balance. This progressive deterioration underscores the niche's role in age-related tissue decline.

Paracrine Signaling in Pathology

Dysregulation in Cancer

Paracrine signaling plays a pivotal role in oncogenesis through mechanisms such as ligand overexpression and shifts from paracrine to loops within tumors. For instance, fibroblast growth factors (FGFs) are frequently overexpressed in cancers, promoting via paracrine effects on endothelial cells, which supports tumor vascularization and growth. In many tumors, genetic alterations disrupt normal paracrine regulation, leading to autocrine activation where cancer cells produce and respond to their own signaling molecules, thereby enhancing proliferation and survival. These dysregulations often involve key paracrine families, including , Wnt, TGF-β, and FGF (RTK) pathways. Aberrant activation of specific paracrine signaling families drives tumorigenesis in distinct cancers. In , loss-of-function mutations in the receptor lead to constitutive pathway activation, enabling paracrine signaling that promotes tumor growth and stromal remodeling. Similarly, in , APC loss results in uncontrolled Wnt signaling, which sustains paracrine interactions that facilitate adenoma-to-carcinoma progression. TGF-β exhibits a dual role: acting as a tumor suppressor in early stages by inhibiting epithelial cell proliferation through paracrine cues, but switching to a promoter in advanced disease by fostering immune evasion and stromal activation. FGF RTKs contribute to progression in and cancers, where amplified receptors respond to paracrine ligands, driving cell motility and metastasis. The amplifies these effects through stromal paracrine signaling, particularly from cancer-associated fibroblasts (CAFs), which secrete hepatocyte growth factor (HGF) to activate c-MET receptors on tumor cells, enhancing and therapy resistance. In , paracrine TGF-β signaling induces epithelial-mesenchymal transition (EMT) in cancer cells, enabling dissemination and colonization of distant sites by upregulating motility genes and extracellular matrix remodeling. Therapeutic strategies targeting these dysregulations include inhibitors like vismodegib, which blocks SMO to regress advanced basal cell carcinomas by disrupting paracrine loops.

Involvement in Other Diseases

Paracrine signaling through transforming growth factor-β (TGF-β) is pivotal in the pathogenesis of , particularly in (IPF), where it drives excessive scar formation in the lungs. In IPF, activated fibroblasts and secrete TGF-β, which acts on neighboring epithelial and mesenchymal cells to induce epithelial-mesenchymal transition and promote the deposition of components like , leading to progressive tissue stiffening and architectural distortion. This paracrine loop is amplified by interactions between hyperplastic lung fibroblasts from IPF patients, which release interleukin-6 (IL-6) to activate signaling in adjacent normal fibroblasts, thereby enhancing TGF-β responsiveness and sustaining fibrotic remodeling. Studies have shown that disrupting this TGF-β-mediated paracrine reduces myofibroblast differentiation and matrix production in experimental models of lung fibrosis. In autoimmune diseases such as (RA), paracrine signaling via the IL-6/JAK-STAT pathway exacerbates synovial and joint damage. Synovial macrophages and in RA joints secrete IL-6, which binds to the IL-6 receptor on neighboring cells, triggering JAK-mediated phosphorylation of and promoting the production of pro-inflammatory mediators that amplify immune cell recruitment and . This paracrine IL-6 loop fosters a self-perpetuating inflammatory microenvironment, contributing to formation and cartilage erosion, as evidenced by elevated IL-6 levels correlating with disease severity in RA patients. Inhibition of JAK-STAT signaling in preclinical models disrupts this paracrine network, reducing synovial and inflammatory output. Paracrine dysregulation of (FGF) and Hedgehog signaling contributes to neurodegeneration in (PD), where diminished signaling fails to provide adequate to neurons. In PD, reduced secretion of FGF ligands, such as FGF21, from and other glial cells impairs paracrine activation of FGFR1 receptors on neurons, leading to mitochondrial dysfunction, blood-brain barrier disruption, and accelerated neuronal loss in the . Similarly, sonic Hedgehog (Shh) signaling from neurons declines in PD models, disrupting non-cell-autonomous paracrine support that maintains neuronal and synthesis, resulting in progressive motor deficits. Overexpression of FGF21 in experimental PD restores this paracrine , improving motor function and reducing through SIRT1 activation. In cardiovascular diseases, bone morphogenetic proteins (BMPs) exert paracrine effects that promote vascular , a key feature of and chronic kidney disease-associated vasculopathy. Vascular cells (VSMCs) in calcified arteries secrete BMP-2, which binds to BMP receptors on adjacent VSMCs and endothelial cells, inducing osteogenic differentiation and mineralization via Smad-dependent pathways. This paracrine BMP signaling accelerates intimal and medial , as demonstrated in BMP-2 transgenic models where enhanced signaling correlates with increased plaque and vascular stiffness. Wnt signaling further contributes to through paracrine mechanisms, with Wnt5a secreted by macrophages activating non-canonical pathways in endothelial and cells to heighten , formation, and lesion progression. Paracrine signaling by adipokines in underlies metabolic dysfunction in , driving local and . In obese visceral fat, adipocytes hypersecrete and pro-inflammatory adipokines like , which act paracrine on adjacent macrophages and endothelial cells to activate pathways, promoting release and impaired in nearby tissues. Conversely, reduced paracrine from hypertrophic adipocytes fails to suppress and enhance insulin sensitivity in the obese microenvironment, exacerbating systemic . This dysregulated adipokine paracrine network correlates with remodeling and contributes to comorbidities like , as shown in human cohorts where elevated / ratios predict inflammatory progression.

Research Methods and Future Directions

Experimental Techniques

Experimental techniques for studying paracrine signaling encompass a range of , , and advanced imaging and approaches designed to capture the spatial and temporal dynamics of secretion, diffusion, and receptor between neighboring cells. These methods address the challenges of mimicking short-range signaling in controlled settings, allowing researchers to dissect the contributions of specific factors to cellular responses without the confounding effects of long-distance endocrine signals. Key advancements have focused on systems that preserve physiological gradients and interactions while enabling precise manipulation and measurement. In vitro assays provide foundational tools for isolating paracrine effects. Co-culture systems enable direct or indirect interactions between cell types, facilitating the study of secreted factors without physical contact. For instance, indirect co-cultures using conditioned media or segregated chambers allow quantification of paracrine influences on target cells, such as enhanced proliferation or differentiation in response to soluble . Transwell assays simulate gradients by separating donor and receiver cells with a porous , permitting ligand passage while preventing ; this setup has been widely used to model tumor-stroma interactions where cancer cells secrete growth factors that promote activation. Enzyme-linked immunosorbent assay () detects and quantifies paracrine ligands in culture supernatants, offering high sensitivity for low-abundance proteins like cytokines or growth factors, though it requires validation with functional readouts to confirm bioactivity. In vivo studies leverage genetic tools in model organisms, particularly mice, to probe paracrine signaling in native tissues. The Cre-loxP system enables conditional knockouts of or receptor genes in specific cell populations, revealing paracrine dependencies; for example, tissue-specific deletion of Wnt pathway components has demonstrated their role in epithelial-mesenchymal crosstalk during development. Lineage tracing techniques, often combined with Cre-lox reporters, track the progeny of signaling-competent cells, helping map how paracrine cues influence cell fate decisions, such as in cardiac or neural tissues where labeled progenitors respond to local signals. Advanced imaging methods visualize paracrine dynamics in real time. Live-cell Förster resonance energy transfer (FRET) biosensors monitor intracellular signaling cascades triggered by paracrine s, such as ERK activation in response to growth factors, providing spatiotemporal resolution of signal propagation across cell populations. allows precise control of release or receptor activation using light-sensitive proteins, enabling of causal relationships in paracrine circuits, like opto-activated Ras-ERK pathways that induce secondary factor . Omics approaches, particularly single-cell sequencing (scRNA-seq), infer paracrine networks by integrating ligand-receptor expression patterns across heterogeneous cell types. Tools like CellChat analyze scRNA-seq data to predict communication strength and directionality, identifying key axes such as TGF-β-mediated interactions in tumor microenvironments. These methods complement functional assays by revealing emergent network properties. A persistent challenge in paracrine research is distinguishing it from , where ligands act on the producing cell itself. Strategies include using receptor blockers or genetic ablation in donor cells to isolate effects, or microcavity platforms that spatially segregate signals, ensuring observed responses arise from intercellular rather than self-stimulation.

Therapeutic Targeting

Therapeutic targeting of paracrine signaling has emerged as a promising strategy in and fibrotic diseases, focusing on inhibitors that disrupt dysregulated ligand-receptor interactions to halt pathological cell communication. (RTK) inhibitors, particularly those targeting fibroblast growth factor receptors (FGFRs), exemplify this approach by blocking paracrine FGF signaling implicated in tumor proliferation. Erdafitinib, an oral FGFR1-4 inhibitor, received accelerated FDA approval in 2019 for adults with locally advanced or metastatic urothelial harboring susceptible FGFR3 or FGFR2 alterations who progressed during or following platinum-containing ; full approval followed in January 2024 based on improved overall survival in confirmatory trials. In pathway, (SMO) antagonists target paracrine signaling driven by Sonic Hedgehog ligands, which promote (BCC) growth. Vismodegib, the first-in-class SMO inhibitor, was granted FDA approval in 2012 for treatment of adults with metastatic BCC or locally advanced BCC unsuitable for or , demonstrating objective response rates of approximately 30-50% in pivotal trials. However, clinical resistance often develops within a year, primarily due to acquired SMO mutations in up to 50% of cases, which sustain pathway activation despite inhibition; strategies to overcome this include combination therapies or next-generation inhibitors like sonidegib, approved in 2015. For Wnt and TGF-β pathways, inhibitors aim to curb paracrine signals fostering tumor progression and fibrosis. Porcupine inhibitors like ETC-159, which block Wnt ligand secretion by inhibiting the O-acyltransferase PORCN, are under investigation; as of 2025, the combination of ETC-159 with pembrolizumab has completed dose escalation in phase 1B trials for advanced solid tumors, with preliminary antitumor activity and manageable toxicity reported in microsatellite-stable colorectal cancer patients from 2023 data, and further expansion ongoing in select indications. Anti-TGF-β antibodies, such as fresolimumab, neutralize all TGF-β isoforms to mitigate fibrotic paracrine effects; in a phase 1 trial for early diffuse systemic sclerosis, subcutaneous fresolimumab improved modified Rodnan skin scores by up to 20% and reduced biomarkers like αvβ6 integrin, though development has been limited by immune-related adverse events. Post-2020 preclinical data support Wnt inhibition in inflammatory bowel disease (IBD), with small-molecule inhibitors like XAV939 reducing colitis severity in dextran sulfate sodium models by suppressing β-catenin/SOX9 signaling, paving the way for potential clinical translation. Nanoparticle-based delivery systems enhance local paracrine modulation, particularly in , by enabling targeted release of signaling modulators to nearby cells without systemic exposure. Nitric oxide-releasing nanoparticles, for instance, accelerate diabetic wound closure in murine models by pleiotropically reducing , enhancing via paracrine VEGF signaling, and promoting re-epithelialization, with closure rates improved by 50% compared to controls. Emerging future directions include -based gene editing to disrupt paracrine signaling genes, offering precise therapeutic modulation in diseases like cancer where pathway alterations drive progression. Preclinical applications have demonstrated / knockout of Wnt or TGF-β pathway components in immune cells, enhancing antitumor paracrine effects in models by boosting secretion and T-cell infiltration. Clinical translation remains early-stage, with ongoing trials exploring -edited cells for broader paracrine-targeted therapies. Additionally, advances in computational tools, such as updated ligand-receptor inference methods (e.g., enhanced CellChat or NicheNet), and novel optogenetic systems are enabling more accurate modeling and control of paracrine networks.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK538154/
  2. https://www.ncbi.nlm.nih.gov/books/NBK10071/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC2728016/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC12186372/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC24899/
  6. https://www.ncbi.nlm.nih.gov/books/NBK9924/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC4686426/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10901993/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC2229370/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6651758/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4393358/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2600921/
  13. https://www.ncbi.nlm.nih.gov/books/NBK26813/
  14. https://jme.bioscientifica.com/content/22/3/207.full.pdf
  15. https://pubmed.ncbi.nlm.nih.gov/15982853/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3962617/
  17. https://www.science.org/doi/10.1126/science.284.5415.770
  18. https://pubmed.ncbi.nlm.nih.gov/10221902/
  19. https://www.ahajournals.org/doi/10.1161/01.res.77.3.638
  20. https://doi.org/10.1101/sqb.1995.060.01.003
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC2613191/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC4874329/
  23. https://www.ncbi.nlm.nih.gov/books/NBK554403/
  24. https://www.ncbi.nlm.nih.gov/books/NBK10043/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4830124/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC2895425/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC5533627/
  28. https://www.nature.com/articles/s41392-020-00222-7
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3684054/
  30. https://www.pnas.org/doi/10.1073/pnas.0437842100
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC1867116/
  32. https://pubmed.ncbi.nlm.nih.gov/9056643/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC3705708/
  34. https://journals.biologists.com/dev/article/146/10/dev166892/48815/Biochemical-mechanisms-of-vertebrate-hedgehog
  35. https://genesdev.cshlp.org/content/22/18/2454.full.html
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4214369/
  37. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.774291/full
  38. https://www.uniprot.org/uniprotkb/Q15465/entry
  39. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2017.00014/full
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10278198/
  41. https://www.science.org/doi/10.1126/science.aas8935
  42. https://www.nature.com/articles/s41392-023-01559-5
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC7174405/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC8453165/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC6465139/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC9404457/
  47. https://www.nature.com/articles/s41467-021-24731-3
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC3578231/
  49. https://journals.biologists.com/dev/article/150/3/dev201352/286996/The-role-of-Evi-Wntless-in-exporting-Wnt-proteins
  50. https://www.sciencedirect.com/science/article/pii/S0012160611013698
  51. https://www.sciencedirect.com/science/article/pii/S089865681300363X
  52. https://pubmed.ncbi.nlm.nih.gov/15331234/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC3504444/
  54. https://www.pnas.org/doi/10.1073/pnas.2218238120
  55. https://www.sciencedirect.com/science/article/pii/S2352304223000557
  56. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/transforming-growth-factor-beta-superfamily
  57. https://www.nature.com/articles/s41392-024-01764-w
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC4717672/
  59. https://www.sciencedirect.com/science/article/pii/S0014579312004036
  60. https://genesdev.cshlp.org/content/14/6/627.full
  61. https://www.sciencedirect.com/science/article/abs/pii/S008367291500031X
  62. https://www.sciencedirect.com/science/article/pii/S1534580709000860
  63. https://www.sciencedirect.com/science/article/abs/pii/S135961010300100X
  64. https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2012.03.063
  65. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0782-4
  66. https://www.ncbi.nlm.nih.gov/books/NBK538532/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC2536775/
  68. https://portlandpress.com/biochemj/article/437/2/199/45561/Fibroblast-growth-factors-and-their-receptors-in
  69. https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2022.860985/full
  70. https://genesdev.cshlp.org/content/30/7/751.full
  71. https://www.nature.com/articles/s41392-021-00791-1
  72. https://www.science.org/doi/10.1126/science.8197455
  73. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.00500/full
  74. https://www.mdpi.com/2076-3271/1/1/20
  75. https://pubmed.ncbi.nlm.nih.gov/11779460/
  76. https://www.nature.com/articles/s41392-025-02142-w
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC2634250/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC7392137/
  79. https://journals.biologists.com/dev/article/146/10/dev176073/48838/Mechanisms-of-intercellular-Wnt-transport
  80. https://www.nature.com/articles/ncomms6846
  81. https://www.nature.com/articles/cr2008328
  82. https://journals.biologists.com/dev/article/135/15/2489/64793/Pattern-formation-in-the-vertebrate-neural-tube-a
  83. https://www.embopress.org/doi/10.1038/emboj.2009.12
  84. https://genesdev.cshlp.org/content/29/14/1463.full.html
  85. https://journals.biologists.com/dev/article/145/11/dev146589/48471/Wnt-signaling-in-development-and-tissue
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC8753366/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC2919945/
  88. https://journals.biologists.com/dev/article/137/22/3731/44062/FGF-signalling-diverse-roles-during-early
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC2810618/
  90. https://www.pnas.org/doi/10.1073/pnas.0906352106
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC11150145/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC7027765/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC5938667/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC4183920/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC8968572/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC9086899/
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC5802812/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC4160113/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC3664927/
  100. https://www.nature.com/articles/s41392-023-01442-3
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC6262325/
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC3072659/
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC4899619/
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC4228698/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC3926427/
  106. https://www.nature.com/articles/s41419-018-0922-1
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC6600375/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC5278761/
  109. https://www.atsjournals.org/doi/10.1513/pats.201201-003AW
  110. https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-1319-0
  111. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.918771/full
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC7465448/
  113. https://bmcmolcellbiol.biomedcentral.com/articles/10.1186/s12860-020-00317-7
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC12358124/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC12570635/
  116. https://www.sciencedirect.com/science/article/pii/S0896627312004849
  117. https://pubmed.ncbi.nlm.nih.gov/41152735/
  118. https://www.ahajournals.org/doi/10.1161/atvbaha.110.206185
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC8185454/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC4252768/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC9913478/
  122. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.578966/full
  123. https://www.e-dmj.org/journal/view.php?number=137
  124. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma
  125. https://aacrjournals.org/clincancerres/article/19/9/2289/78105/U-S-Food-and-Drug-Administration-Approval
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC4357167/
  127. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2601
  128. https://www.jci.org/articles/view/77958
  129. https://www.spandidos-publications.com/10.3892/etm.2024.12774
  130. https://pubs.acs.org/doi/10.1021/acscentsci.6b00371
  131. https://www.sciencedirect.com/science/article/pii/S0925443923002387
Add your contribution
Related Hubs
User Avatar
No comments yet.